1.60
-0.01 (-0.62%)
| Penutupan Terdahulu | 1.61 |
| Buka | 1.61 |
| Jumlah Dagangan | 290,632 |
| Purata Dagangan (3B) | 2,440,125 |
| Modal Pasaran | 3,612,848 |
| Harga / Buku (P/B) | 0.200 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 26 Aug 2025 - 1 Sep 2025 |
| EPS Cair (TTM) | -6.60 |
| Nisbah Semasa (MRQ) | 9.02 |
| Aliran Tunai Operasi (OCF TTM) | -5.22 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -3.82 M |
| Pulangan Atas Aset (ROA TTM) | -23.12% |
| Pulangan Atas Ekuiti (ROE TTM) | -49.58% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menurun | Menurun |
| Biotechnology (Global) | Menurun | Menurun | |
| Stok | Galmed Pharmaceuticals Ltd. | Bercampur | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | -2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | -1.0 |
| Osilator Teknikal | 2.0 |
| Purata | -0.75 |
|
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 2.90% |
| % Dimiliki oleh Institusi | 2.55% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Tsfg, Llc | 31 Mar 2025 | 17 |
| Elevation Wealth Partners, Llc | 31 Mar 2025 | 1 |
| Dogwood Wealth Management Llc | 31 Mar 2025 | 1 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |